Combining complementary technologies and expertise… Accelerating mRNA technology development and commercialization
SML Biopharm announced on the 6th that it has signed a memorandum of understanding (MOU) with CATUG, a global mRNA CRO/CDMO headquartered in Basel, Switzerland. Through this collaboration, the two companies plan to combine complementary technologies and expertise to accelerate mRNA technology development and commercialization.
Under the MOU, CATUG will bring its accumulated expertise and experience in nucleic acid and LNP research, development, and manufacturing, while SML Biopharm will participate in the collaboration based on its innovative mRNA-LNP platform and strong presence in the Korean market. The two companies are expected to secure a leading position in the global biohealth industry and create new opportunities through this partnership.
Nam Jae-hwan, CEO of SML Biopharm, said, “This collaboration will be an important milestone for both SML Biopharm and CATUG,” adding, “By leveraging CATUG’s expertise, we are confident we can accelerate drug development and further advance our existing pipeline.” He added, “By combining our capabilities, we will drive innovation in the biohealth industry and open up new possibilities in the global market.”
Lin Jin, co-founder and CEO of CATUG, said, “We see great potential in collaborating with SML Biopharm,” and added, “By combining our technological capabilities with SML Biopharm’s influence in the Korean market, we will provide patients with innovative therapies and expand our presence in Korea.”
The two companies have set joint research and development, and the marketing and sales activities of life-science tools and contract services as their main objectives for this collaboration. Through this, they are expected to establish themselves as leaders in the global market for mRNA-based therapeutics and advanced drug delivery systems.
SML Biopharm was founded in 2021 by Professor Nam Jae-hwan of the Catholic University and, based on differentiated mRNA technologies, is developing mRNA vaccines and therapeutics across various fields. It is part of the Samkwang Biotree Group and has related companies including Samkwang Medical Foundation, Samkwang LabTree, SML Meditree, and SML Genitree.
Lee Kwon-gu, Yakup News
https://www.yakup.com/news/?mode=view&cat=12&cat2=121&cat3=0&nid=303385
